These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 6085395)

  • 41. Therapy of behavioral disorders in Parkinson's disease.
    Valldeoriola F; Molinuevo J
    Biomed Pharmacother; 1999 Apr; 53(3):149-53. PubMed ID: 10349504
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Depressive pseudodementia in early Parkinson's disease: lessons from a case with long-term follow-up].
    Giménez-Roldán S; Mateo D; Dobato JL
    Neurologia; 1997 Mar; 12(3):130-5. PubMed ID: 9198454
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Behavioral and psychiatric symptoms associated with Huntington's disease.
    Cummings JL
    Adv Neurol; 1995; 65():179-86. PubMed ID: 7872139
    [No Abstract]   [Full Text] [Related]  

  • 44. Subcortical dementia. Review of an emerging concept.
    Cummings JL; Benson DF
    Arch Neurol; 1984 Aug; 41(8):874-9. PubMed ID: 6235797
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rivastigmine in Parkinson's disease dementia.
    Chitnis S; Rao J
    Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):941-55. PubMed ID: 19619073
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neuropsychiatry of Huntington's disease and other basal ganglia disorders.
    Rosenblatt A; Leroi I
    Psychosomatics; 2000; 41(1):24-30. PubMed ID: 10665265
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cerebrospinal fluid levels of diazepam-binding inhibitor in neurodegenerative disorders with dementia.
    Ferrarese C; Appollonio I; Frigo M; Meregalli S; Piolti R; Tamma F; Frattola L
    Neurology; 1990 Apr; 40(4):632-5. PubMed ID: 2138718
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5HIAA) during L-dopa therapy of Parkinson's disease.
    van Woert MH; Bowers MB
    Neurology; 1970 Apr; 20(4):377. PubMed ID: 5534981
    [No Abstract]   [Full Text] [Related]  

  • 49. The effects of age and serotonergic activity on slow-wave sleep in depressive illness.
    Benson KL; Faull KF; Zarcone VP
    Biol Psychiatry; 1993 Jun 1-15; 33(11-12):842-4. PubMed ID: 7690599
    [No Abstract]   [Full Text] [Related]  

  • 50. Diminished levels of ventricular fluid norepinephrine metabolite and somatostatin in childhood-onset dystonia.
    Wolfson LI; Sharpless NS; Thal LJ
    Adv Neurol; 1988; 50():177-81. PubMed ID: 2456674
    [No Abstract]   [Full Text] [Related]  

  • 51. Depression and Parkinson's disease: possible role of serotonergic mechanisms.
    Kostić VS; Djuricić BM; Covicković-Sternić N; Bumbasirević L; Nikolić M; Mrsulja BB
    J Neurol; 1987 Feb; 234(2):94-6. PubMed ID: 2435855
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Coexisting dementia and depression in Parkinson's disease.
    Sano M; Stern Y; Williams J; Coté L; Rosenstein R; Mayeux R
    Arch Neurol; 1989 Dec; 46(12):1284-6. PubMed ID: 2480103
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Repertory grid and biochemical characterization of depression: a comparison of case reports.
    Yesavage JA; Slater P; Berger PA
    J Clin Psychiatry; 1979 May; 40(5):232-5. PubMed ID: 438147
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Psychiatric disorders in parkinsonism. 1. Functional illnesses and personality.
    Harvey NS
    Psychosomatics; 1986 Feb; 27(2):91-3, 97-8, 102-3. PubMed ID: 3513232
    [No Abstract]   [Full Text] [Related]  

  • 55. [Depression and dementia in Parkinson's disease].
    Bermejo F; Enguita MA; del Ser T
    Med Clin (Barc); 1986 Jun; 87(3):90-5. PubMed ID: 3736230
    [No Abstract]   [Full Text] [Related]  

  • 56. [Biochemical mechanisms of extrapyramidal-motoric effect of haloperidol in man].
    Eben E; Ackenheil M; Raese J; Rüther E
    Arzneimittelforschung; 1974 Aug; 24(8):1133-5. PubMed ID: 4479374
    [No Abstract]   [Full Text] [Related]  

  • 57. The current status of biological criteria for classifying the depressive disorders and predicting responses to treatment.
    Schildkraut JJ
    Psychopharmacol Bull; 1974 Jan; 10(1):5-25. PubMed ID: 4590871
    [No Abstract]   [Full Text] [Related]  

  • 58. L-acetyl-carnitine in Huntington's disease: double-blind placebo controlled crossover study of drug effects on movement disorder and dementia.
    Goety CG; Tanner CM; Cohen JA; Thelen JA; Carroll VS; Klawans HL; Fariello RG
    Mov Disord; 1990; 5(3):263-5. PubMed ID: 2143808
    [No Abstract]   [Full Text] [Related]  

  • 59. Treatment with disulfiram in huntington's chorea.
    Mattsson B; Bertilsson L
    Acta Psychiatr Scand Suppl; 1974; 255():261-8. PubMed ID: 4282557
    [No Abstract]   [Full Text] [Related]  

  • 60. Huntington's chorea in Bedfordshire, England.
    Heathfield KW; Mackenzie IC
    Guys Hosp Rep; 1971; 120(4):295-309. PubMed ID: 4261437
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.